LEPU Medical NASOCHECK comfort self-test (pack of 1)
Item number 252
|Minimum quantity: 50||EUR 1.21|
|Minimum quantity: 250||EUR 1.17|
|Minimum quantity: 500||EUR 1.13|
|Minimum quantity: 2500||EUR 1.08|
|Minimum quantity: 5000||EUR 1.04|
LEPU Medical Antigen Self-Test
(Nose swab self-test, individually packed)
Thanks to its easy handling with swab in the anterior nasal cavity and the uncomplicated evaluation without tubes, the NASOCHECK comfort rapid test is perfectly optimized for self-testing.
Thanks to its simple handling with swab in the anterior nasal cavity and the uncomplicated evaluation without tubes, this rapid test is perfect for self-testing. Test results are available within 15 minutes and the result is displayed by means of a test strip. The evaluation of the LEPU Antigen Rapid Test is particularly easy and avoids misinterpreted test results.
The LEPU Antigen Rapid Test detects the nucleocapsid (N) protein of the coronavirus. A test strip is used to display the test result. The higher the volume of this protein, the darker the color of the test strip.
Sample collection via swab rolled only 2 cm deep in both nostrils
Official listing in the Federal Institute for Drugs and Medical Devices
Rapid identification of infected persons
Particularly simple and shear-free
Tested by the Paul Ehrlich Institute
Individually packaged, EAN printed
The sensitivity of a clinical test indicates the percentage of diseased patients in which the disease is actually detected. The higher the sensitivity, the more reliable the test.
The specificity of a clinical test indicates the probability that actually healthy patients are detected as healthy in the test.
The LEPU Antigen Rapid Test is listed at the Federal Institute for Drugs and Medical Devices (BfArM).
This list includes all antigen tests for the direct pathogen detection of the SARS-CoV-2 coronavirus that meet the preguards of the Medical Devices Act (MPG) in Germany as well as the established minimum criteria for antigen tests by the Robert Koch Institute (RKI) and the Paul Erhlich Institute. Tests on this list are eligible for reimbursement under the federal government's National Testing Strategy.
The LEPU Antigen Rapid Test has been evaluated and tested by the Paul Ehrlich Institute.
The Paul Ehrlich Institute performs an additional evaluation of antigen rapid tests on the BfArM list in the laboratory. If the test passes this evaluation, it will be listed in the Paul Ehrlich Institute's "Comparative Evaluation of the Sensitivity of SARS-CoV-2 Antigen Rapid Tests" list.
If the test does not pass this evaluation, the product will be removed from the BfArM list.